Rankings
▼
Calendar
ICCC Q3 2023 Earnings — ImmuCell Corporation Revenue & Financial Results | Market Cap Arena
ICCC
ImmuCell Corporation
$60M
Q3 2023 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$5M
+12.5% YoY
Gross Profit
$1M
23.5% margin
Operating Income
-$1M
-21.9% margin
Net Income
-$940,000
-17.4% margin
EPS (Diluted)
$-0.12
QoQ Revenue Growth
+52.8%
Cash Flow
Operating Cash Flow
-$507,754
Free Cash Flow
-$928,269
Stock-Based Comp.
$96,434
Balance Sheet
Total Assets
$45M
Total Liabilities
$19M
Stockholders' Equity
$26M
Cash & Equivalents
$2M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$5M
$5M
+12.5%
Gross Profit
$1M
$2M
-31.4%
Operating Income
-$1M
-$616,790
-92.0%
Net Income
-$940,000
-$655,078
-43.5%
Geographic Segments
UNITED STATES
$5M
100%
← FY 2023
All Quarters
Q4 2023 →